Alzheimer’s disease, a progressive neurodegenerative disorder, stands as the most common cause of dementia globally, affecting millions and placing an immense burden on patients, caregivers, and healthcare systems. Characterized by a gradual decline in memory, thinking, and reasoning skills, the disease is relentless, with no cure currently available. For decades, treatments primarily focused on symptomatic relief, offering limited impact on the underlying disease progression. The approval of Leqembi (lecanemab) in 2023 marked a pivotal shift, representing one of the first disease-modifying therapies demonstrated to slow cognitive decline by targeting the amyloid-beta plaques believed to be a central pathology of the disease.<\/p>\n
Under its current approval, Leqembi is administered as an intravenous infusion every other week for the initial 18 months of treatment. Following this induction phase, patients may transition to a maintenance regimen, which includes options for monthly intravenous infusions or weekly subcutaneous injections. The initial IV administration necessitates regular visits to a healthcare facility, where the infusion must be supervised by a medical professional. This requirement can pose significant logistical, financial, and emotional challenges for patients and their caregivers, including travel time, lost workdays, and the inherent stress of frequent clinic visits.<\/p>\n
The proposed expanded approval for Leqembi Iqlik would revolutionize this initial phase of treatment. If approved, patients could commence treatment with the weekly subcutaneous injection, allowing for self-administration at home by either the patient or a trained caregiver. This paradigm shift holds the potential to dramatically enhance accessibility, convenience, and the overall quality of life for individuals grappling with early Alzheimer’s and their support networks.<\/p>\n
The Scientific Foundation: Leqembi’s Mechanism and Efficacy<\/strong><\/p>\n Leqembi is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody that selectively targets and clears amyloid-beta protofibrils, which are soluble aggregates of amyloid-beta protein. These protofibrils are considered highly neurotoxic and are believed to be an upstream driver of Alzheimer’s pathology, leading to the formation of insoluble amyloid plaques and subsequent neurodegeneration. By binding to and facilitating the removal of these protofibrils, lecanemab aims to reduce the amyloid burden in the brain and, consequently, slow the progression of cognitive and functional decline.<\/p>\n The initial full FDA approval of Leqembi in July 2023 was primarily supported by robust data from the Phase 3 Clarity AD clinical trial (NCT03887455). This global, confirmatory, placebo-controlled, double-blind, parallel-group study enrolled 1,795 participants with early Alzheimer’s disease, encompassing both mild cognitive impairment due to Alzheimer’s and mild Alzheimer’s dementia with confirmed amyloid pathology. Over 18 months, participants received either bi-weekly intravenous infusions of lecanemab or a placebo.<\/p>\n The Clarity AD trial demonstrated statistically significant and clinically meaningful results. The primary endpoint, change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, showed a 27% reduction in clinical decline for patients treated with lecanemab compared to placebo after 18 months. The CDR-SB is a comprehensive scale that assesses cognitive and functional abilities across six domains, including memory, orientation, judgment, community affairs, home and hobbies, and personal care. This 27% reduction, while modest, represented a tangible slowing of disease progression, offering a glimmer of hope in a field long marked by therapeutic stagnation.<\/p>\n Furthermore, secondary endpoints in Clarity AD reinforced lecanemab’s efficacy. Significant reductions in amyloid plaque levels, measured by amyloid PET imaging, were observed in the treatment arm, confirming the drug’s mechanism of action in clearing brain amyloid. Additionally, positive trends were noted in other cognitive and functional assessments, such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 14 (ADAS-Cog14) and the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Mild Cognitive Impairment (ADCS-MCI ADL) scale. These findings collectively underscored Leqembi’s potential as a disease-modifying therapy.<\/p>\n The Case for Subcutaneous Administration: Data and Convenience<\/strong><\/p>\n The current sBLA for Leqembi Iqlik is supported by data derived from sub-studies conducted as part of the open-label extension (OLE) of the Clarity AD trial. In these sub-studies, researchers evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, as well as the safety and tolerability, of the weekly subcutaneous formulation of lecanemab compared to the approved every-other-week intravenous formulation.<\/p>\n Crucially, the data demonstrated that the subcutaneous formulation delivered comparable amounts of the drug into the bloodstream (PK comparability) and achieved similar reductions in amyloid biomarkers (PD comparability) as the intravenous formulation. This indicates that the subcutaneous route of administration is equally effective in engaging the target (amyloid protofibrils) and clearing amyloid from the brain. Furthermore, the clinical, biomarker, and safety data were found to be consistent between the two formulations, suggesting no significant trade-offs in efficacy or safety profiles when switching to the subcutaneous route.<\/p>\n The implications of this comparability are profound. As stated by Biogen and Eisai in their press release, an FDA approval for this expansion "would enable patients and care partners to choose [subcutaneous] administration at home for both treatment initiation and the currently approved maintenance therapy (360 mg), offering the option of [subcutaneous] or [infusion] administration throughout the entire treatment journey." This flexibility empowers patients and caregivers, granting them greater autonomy in managing a chronic, debilitating disease.<\/p>\n The Timeline of Lecanemab’s Journey<\/strong><\/p>\n The journey of lecanemab from laboratory research to potential widespread at-home administration has been a long and intricate one, reflecting the complexities of Alzheimer’s drug development:<\/p>\n Broader Implications for Patients, Caregivers, and Healthcare Systems<\/strong><\/p>\n The potential approval of Leqembi Iqlik for initial subcutaneous administration carries multifaceted implications:<\/p>\n Challenges and Considerations<\/strong><\/p>\n Despite the clear advantages, the expanded approval of Leqembi Iqlik will also present new challenges and considerations:<\/p>\n Global Context and Future Outlook<\/strong><\/p>\n Leqembi’s impact extends beyond U.S. borders. According to Biogen and Eisai, Leqembi has already received approval in 53 countries worldwide and is currently under review in another seven. This global reach underscores the universal unmet need for effective Alzheimer’s treatments and the broad recognition of lecanemab’s therapeutic potential. The approval of a subcutaneous option in the U.S. would likely influence regulatory decisions and treatment paradigms in other nations, further expanding access globally.<\/p>\n The field of Alzheimer’s research is rapidly evolving. While anti-amyloid therapies like Leqembi represent a significant breakthrough, ongoing research is exploring other targets, including tau pathology, neuroinflammation, and synaptic dysfunction. The ultimate future of Alzheimer’s treatment may involve combination therapies, personalized medicine approaches, and even earlier interventions in pre-symptomatic stages. The potential expanded approval of Leqembi Iqlik is a crucial step in this journey, offering a more patient-centric approach to managing a devastating disease and reinforcing the commitment to improving the lives of those affected by Alzheimer’s. The impending FDA decision is eagerly awaited by patients, caregivers, and the global medical community, poised to mark another significant milestone in the fight against Alzheimer’s disease.<\/p>\n","protected":false},"excerpt":{"rendered":" The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) submitted by Biogen and Eisai for Leqembi Iqlik (lecanemab-irmb), a subcutaneous injection version of the approved Alzheimer’s disease treatment Leqembi. This application seeks to expand approval for the weekly subcutaneous injection to be used by patients from the very …<\/p>\n","protected":false},"author":1,"featured_media":5833,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39],"tags":[40,360,43,41,359,66,366,362,361,42,552,358,363,223],"newstopic":[],"class_list":["post-5834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alzheimers-dementia-care","tag-alzheimers","tag-approval","tag-cognitive-health","tag-dementia-care","tag-expanded","tag-home","tag-initiation","tag-iqlik","tag-leqembi","tag-memory-care","tag-offering","tag-reviews","tag-subcutaneous","tag-treatment"],"_links":{"self":[{"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/posts\/5834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5834"}],"version-history":[{"count":0,"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/posts\/5834\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=\/wp\/v2\/media\/5833"}],"wp:attachment":[{"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5834"},{"taxonomy":"newstopic","embeddable":true,"href":"https:\/\/homecares.net\/index.php?rest_route=%2Fwp%2Fv2%2Fnewstopic&post=5834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"FDA](\"https:\/\/alzheimersnewstoday.com\/wp-content\/uploads\/2024\/04\/Megaphone_700x350.png\")
<\/figure>\n\n
\n
\n